Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1153779 | 0.83 | LMNA (0.61) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1154351 | 0.83 | LMNA (0.52) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1153408 | 0.82 | LMNA (0.56) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1154413 | 0.81 | LMNA (0.61) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1153348 | 0.81 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1154439 | 0.80 | KMT2A (0.51) | LMNASMN1; SMN2MAPTPOLBHPGD | |
| SCHEMBL1154276 | 0.80 | LMNA (0.56) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1154357 | 0.80 | LMNA (0.59) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1153761 | 0.80 | LMNA (0.56) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1153627 | 0.80 | LMNA (0.59) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | BASF SE (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2252606-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009101078-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009101079-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | TPMT, NQO2, TST | LMNA 3704/4885SMN1; SMN2 2777/4885CYP1A2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.